Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Serina Therapeutics (SER)
NYSE MKT:SER
Holding SER?
Track your performance easily
SER Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.81 - $23.92
Previous Close$5.27
Volume5.04K
Average Volume (3M)16.88K
Market Cap
$46.86M
Enterprise Value$52.48M
Total Cash (Recent Filing)$6.06M
Total Debt (Recent Filing)$11.71M
Price to Earnings (P/E)―
Beta-0.70
Next Earnings
Nov 13, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.08
Shares Outstanding8,881,426
10 Day Avg. Volume21,160
30 Day Avg. Volume16,884
Standard Deviation0.24
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-2.82
Price to Sales (P/S)261.48
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue440.99
Enterprise Value/Gross Profit514.49
Enterprise Value/Ebitda-6.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Serina Therapeutics News
PremiumCompany Announcements
Serina Therapeutics CDO Presents at Injectables SummitPremiumCompany Announcements
Serina Therapeutics Names Steven Ledger as Permanent CEO
PremiumCompany Announcements
Serina Therapeutics Interim CEO Attends Global Investment Conference
PremiumCompany Announcements
Serina Therapeutics Welcomes Gregory Curhan as New CFO
PremiumCompany Announcements
Serina Therapeutics CDO to Present at mRNA Summit
Ownership Overview
1.14% Insiders
0.51% Mutual Funds
<0.01% Other Institutional Investors
97.85% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SER FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was $3.81 and its highest was $23.91 in the past 12 months.
What is Serina Therapeutics’s market cap?
Currently, no data Available
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s upcoming earnings report date is Nov 13, 2024 which is 9 days ago.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on Aug 09, 2024. The company reported $0.512 earnings per share for the quarter, beating the consensus estimate of N/A by $0.512.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Overvalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 8,891,976 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of $0.512 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -10.084%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Among the largest hedge funds holding Serina Therapeutics’s share is Defender Capital, LLC.. It holds Serina Therapeutics’s shares valued at N/A.
---
Serina Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 969.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $392.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.78%
Trailing 12-Months
Company Description
Serina Therapeutics
AgeX Therapeutics, Inc. operates as a biotechnology company. It focuses on the development and commercialization of novel therapeutics targeting human aging. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.
---
Technical Analysis
---